


**SUPPLEMENTARY FIGURE**



**Supplementary Figure 1. Kaplan–Meier curves of progression-free survival (PFS) and overall survival (OS) of younger patients (age <65 years) and older patients (age ≥65 years) treated with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). (A) PFS for all EGFR-TKIs; (B) PFS for gefitinib; (C) PFS for erlotinib; (D) PFS for afatinib; (E) OS for all EGFR-TKIs; (F) OS for gefitinib; (G) OS for erlotinib; and (H) OS for afatinib. Abbreviation: CI, confidence interval.**